Related Experiment Video
Updated: Aug 8, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
NFkappaB-dependent chemoresistance in solid tumors
International Journal of Clinical Pharmacology and Therapeutics
|December 7, 2002
Summary
Nuclear Factor kappa B (NFkappaB) activation supports cancer survival and reduces chemotherapy effectiveness. Inhibiting NFkappaB may enhance cancer treatment sensitivity and reduce metastasis, offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- The Rel/NFkappaB family of transcription factors regulates critical cellular processes like inflammation, cell cycle, apoptosis, and oncogenesis.
- Constitutive activation of NFkappaB is prevalent in solid tumors, promoting cancer cell survival and chemoresistance.
Purpose of the Study:
- To review the role of NFkappaB in solid tumor chemoresistance.
- To discuss potential therapeutic strategies targeting NFkappaB for cancer treatment.
Main Methods:
- Literature review of studies investigating NFkappaB's role in cancer.
- Analysis of experimental data on NFkappaB inhibition in cancer models.
Main Results:
- NFkappaB activation confers resistance to chemotherapy and radiation.
- Inhibition of NFkappaB enhances apoptosis sensitivity and can attenuate cancer cachexia and metastasis in preclinical models.
- Some chemotherapeutic drugs can paradoxically induce NFkappaB, reducing their efficacy.
Conclusions:
- NFkappaB is a key player in cancer cell survival and chemoresistance.
- Targeting NFkappaB presents a promising therapeutic avenue for overcoming treatment resistance in various solid tumors.
- Further research and novel agents targeting NFkappaB are under investigation for clinical application.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...